Drug intelligence / Profile preview

AG-3292

Development stage: Unknown
Lead developer: Angarus Therapeutics
Modality: Small Molecules

Overview

AG-3292 is a small molecule drug that functions as an inhibitor of ENPP1 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 1). It was initially developed by Angarus Therapeutics. The drug is currently in preclinical development, and its primary mechanism of action involves the inhibition of ENPP1, a target implicated in immune regulation and potentially relevant to cancer immunotherapy. No clinical trials or approved indications have been reported for AG-3292 as of June 2025[1][4].

Targets

ENPP1

Beyond the preview

Go deeper on AG-3292.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG-3292.

Explore the full profile